Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Our History

    ... FDA approves Vidaza® ( azacitidine ) for use in patients with subtypes of MDS. ... FDA approves Vidaza® (azacitidine) for use in patients with subtypes of MDS. ...

    Page last updated 09/20/2018 - 11:26am.

  2. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce ...

    Research Article last updated 05/22/2017 - 10:52am.

  3. A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients with Myelodysplastic Syndrome (MDS)

    ... of this clinical research study is to learn if azacitidine in combination with pembrolizumab can help to control ... Associated Drug(s):  Azacitidine Phase:  ...

    Clinical Trial last updated 05/14/2018 - 1:57pm.

  4. Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

    ... to compare how 2 different drugs, decitabine and azacitidine , when given on a shorter than standard dosing schedule, may ... Associated Drug(s):  Azacitidine Decitabine ...

    Clinical Trial last updated 05/14/2018 - 1:55pm.

  5. Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

    ... to the current standard treatment, a drug called azacitidine . Although no additional benefit was seen by the new ... by older patients for whom the recently developed drug azacitidine, which can be delivered as an out-patient, represents an important ...

    Research Article last updated 09/29/2017 - 10:32am.

  6. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

    ... AIM: Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were ... of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS: In this ...

    Research Article last updated 02/03/2017 - 10:05am.

  7. Treatments

    ... are three medicines approved in the U.S. to treat MDS. Azacitidine (Vidaza®) and decitabine (Dacogen®) are approved to ...

    Topic section last updated 08/07/2018 - 2:28pm.

  8. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

    Journal Title:  Cell Rep Primary Author:  Unnikrishnan A Author(s):  Unnikris...

    Research Article last updated 08/03/2017 - 9:16am.

  9. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

    Journal Title:  Leuk Lymphoma Primary Author:  Press KR Author(s):  Press KR,...

    Research Article last updated 08/03/2017 - 9:15am.

  10. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

    ... activity in patients with MDS and in vitro synergy with azacitidine . METHODS: A phase 2 randomized, placebo -controlled clinical trial of azacitidine and pracinostat was conducted in patients who had International ...

    Research Article last updated 02/03/2017 - 11:12am.